Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPN-101 in Steroid-Resistant/Refractory aGVHD
NCT04227938Phase 1Terminated
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- May 2020
- Primary completion
- May 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acazicolcept in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Alpine Immune Sciences, Inc. Primary endpoint: Adverse events. Started May 2020; status: terminated.
02
Drugs
acazicolcept
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04227938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227938.